Clinicopathological Analysis of IgA Nephropathy Combined with Other Glomerular Diseases

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2019 Oct 9

PMID 31593089

Citations 2

Authors

Lei Jiang

Bao Dong

Yu Yan

Shuying Zheng

Yanan Hu

Li Zuo

Hongxia Shi

Affiliations

Soon will be listed here.

Abstract

It is not rare to find Immunoglobulin A (IgA) nephropathy (IgAN) combined with other glomerular diseases, which can be called compound IgAN (cIgAN). Till now, clinical-pathological investigation of cIgAN was lacking, especially the severity of "background IgAN lesions." This research aimed to investigate the incidence, clinical and pathological characteristics of cIgAN, and thus improve the understanding of the clinical significance of this combination.Patients with cIgAN diagnosed in Peking University People's Hospital from November 2012 to April 2018 were retrospectively analyzed. Patients with IgAN without compound glomerular diseases (sIgAN) were enrolled as a control group.Among 1407 patients diagnosed with IgAN, 80 (5.69%) were cIgAN patients. Compared with sIgAN, cIgAN patients had a significantly lower prevalence of microscopic hematuria and more urine protein. There were 10 pathological types of glomerular diseases combined with IgAN, led by diabetic nephropathy 37 (46.25%) and membranous nephropathy 14 (17.5%). Histologically, although the mesangial hypercellularity was comparable in 2 groups, cIgAN patients had a lower prevalence of endocapillary proliferation, segmental glomerulosclerosis, and cellular or fibrocellular crescents formation, as well as weaker immunofluorescence intensity for IgA and C3 (all P < .05). Eight out of 27 (29.63%) cIgAN patients with follow-up data (5-48 months) developed irreversible end-stage renal disease requiring dialysis.The order of incidence of concomitant diseases was similar to that of the pure diseases. The "background IgAN associated lesions" except mesangial hypercellularity were relatively mild in cIgAN group. Those might suggest that in some cases, IgAN seems to be a chance finding, and the combined diseases may play a more important role in the clinicopathological features of the patients than the nephritis caused by IgA deposition. While diagnosing IgAN, other combined glomerular diseases need to be carefully considered by nephrologists and pathologists.

Citing Articles

Long term outcome of immunoglobulin A (IgA) nephropathy: A single center experience.

Mohd R, Mohammad Kazmin N, Cader R, Abd Shukor N, Wong Y, Shah S PLoS One. 2021; 16(4):e0249592.

PMID: 33831052 PMC: 8031432. DOI: 10.1371/journal.pone.0249592.

Characterization of IgA Deposition in the Kidney of Patients with IgA Nephropathy and Minimal Change.

Cho W, Park S, Choi S, Jung S, Jeong K, Kim Y J Clin Med. 2020; 9(8).

PMID: 32806730 PMC: 7464421. DOI: 10.3390/jcm9082619.

References

Bantis C, Stangou M, Schlaugat C, Alexopoulos E, Pantzaki A, Memmos D . Is presence of ANCA in crescentic IgA nephropathy a coincidence or novel clinical entity? A case series. Am J Kidney Dis. 2010; 55(2):259-68. DOI: 10.1053/j.ajkd.2009.09.031. View

Roberts I . Pathology of IgA nephropathy. Nat Rev Nephrol. 2014; 10(8):445-54. DOI: 10.1038/nrneph.2014.92. View

Amenomori M, Haneda M, Morikawa J, Nishigaki I, Maeda S, Hidaka H . A case of lipoprotein glomerulopathy successfully treated with probucol. Nephron. 1994; 67(1):109-13. DOI: 10.1159/000187897. View

Chen X, Chen Y, Shi K, Lv Y, Tong H, Zhao G . Comparison of prognostic, clinical, and renal histopathological characteristics of overlapping idiopathic membranous nephropathy and IgA nephropathy versus idiopathic membranous nephropathy. Sci Rep. 2017; 7(1):11468. PMC: 5597578. DOI: 10.1038/s41598-017-11838-1. View

Pan M, Zhang J, You X, Li D, Lv Y, Zhang J . Renal outcomes in primary IgA nephropathy patients with segmental glomerular necrosis: a case-control study. Hum Pathol. 2018; 75:47-54. DOI: 10.1016/j.humpath.2018.01.026. View

DAmico G . The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med. 1987; 64(245):709-27. View

Coppo R, Troyanov S, Bellur S, Cattran D, Cook H, Feehally J . Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014; 86(4):828-36. PMC: 4184028. DOI: 10.1038/ki.2014.63. View

Jiang L, Zhang J, Lv J, Liu G, Zou W, Zhao M . Malignant hypertension in IgA nephropathy was not associated with background pathological phenotypes of glomerular lesions. Nephrol Dial Transplant. 2008; 23(12):3921-7. DOI: 10.1093/ndt/gfn371. View

Trimarchi H, Barratt J, Cattran D, Cook H, Coppo R, Haas M . Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017; 91(5):1014-1021. DOI: 10.1016/j.kint.2017.02.003. View

10.

Kusano T, Takano H, Kang D, Nagahama K, Aoki M, Morita M . Endothelial cell injury in acute and chronic glomerular lesions in patients with IgA nephropathy. Hum Pathol. 2016; 49:135-44. DOI: 10.1016/j.humpath.2015.10.013. View

11.

Liu D, Huang T, Chen N, Xu G, Zhang P, Luo Y . The modern spectrum of biopsy-proven renal disease in Chinese diabetic patients-a retrospective descriptive study. PeerJ. 2018; 6:e4522. PMC: 5877445. DOI: 10.7717/peerj.4522. View

12.

Chen P, Shi S, Qu Z, Zhao N, Xie X, Lv J . Characteristics of patients with coexisting IgA nephropathy and membranous nephropathy. Ren Fail. 2018; 40(1):213-218. PMC: 6014523. DOI: 10.1080/0886022X.2018.1455591. View

13.

Sharma S, Bomback A, Radhakrishnan J, Herlitz L, Stokes M, Markowitz G . The modern spectrum of renal biopsy findings in patients with diabetes. Clin J Am Soc Nephrol. 2013; 8(10):1718-24. PMC: 3789339. DOI: 10.2215/CJN.02510213. View

14.

An Y, Xu F, Le W, Ge Y, Zhou M, Chen H . Renal histologic changes and the outcome in patients with diabetic nephropathy. Nephrol Dial Transplant. 2014; 30(2):257-66. DOI: 10.1093/ndt/gfu250. View

15.

Hu R, Xing G, Wu H, Zhang Z . Clinicopathological features of idiopathic membranous nephropathy combined with IgA nephropathy: a retrospective analysis of 9 cases. Diagn Pathol. 2016; 11(1):86. PMC: 5022150. DOI: 10.1186/s13000-016-0538-7. View

16.

Herlitz L, Bomback A, Stokes M, Radhakrishnan J, DAgati V, Markowitz G . IgA nephropathy with minimal change disease. Clin J Am Soc Nephrol. 2014; 9(6):1033-9. PMC: 4046738. DOI: 10.2215/CJN.11951113. View

17.

Lee S, Rao V, Franklin W, Schiffer M, Aronson A, SPARGO B . IgA nephropathy: morphologic predictors of progressive renal disease. Hum Pathol. 1982; 13(4):314-22. DOI: 10.1016/s0046-8177(82)80221-9. View

18.

Li X, Liang S, Le W, Cheng S, Zeng C, Wang J . Long-term outcome of IgA nephropathy with minimal change disease: a comparison between patients with and without minimal change disease. J Nephrol. 2015; 29(4):567-73. DOI: 10.1007/s40620-015-0242-9. View

19.

Roberts I, Cook H, Troyanov S, Alpers C, Amore A, Barratt J . The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009; 76(5):546-56. DOI: 10.1038/ki.2009.168. View

20.

Tanaka M, Yamada S, Iwasaki Y, Sugishita T, Yonemoto S, Tsukamoto T . Impact of obesity on IgA nephropathy: comparative ultrastructural study between obese and non-obese patients. Nephron Clin Pract. 2009; 112(2):c71-8. DOI: 10.1159/000213084. View